Overview

Ultrasound Guided Intra-sacroiliac Joint Injection: Methylprednisolone Versus Triamcinolone

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
0
Participant gender:
All
Summary
Intra-articular steroids have been also practiced since a long time. These agents have a better and safer profile as compared to oral drugs in terms of adverse effects/contraindications of the later. Moreover, Intra-articular steroids impart a better pain relief by delivering and also delays any surgical intervention thereby improving the patient's quality of life. Without imaging, intra-articular injection has been shown in only 22% of patients so ultrasound, fluoroscopic imaging and computerized tomographic (CT) are required to ensure accuracy. Comparing to other guidance, ultrasound guided injection provides easy, safe, accurate, non-invasive, inexpensive imaging and lacking exposure to radiation.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mansoura University
Criteria
Inclusion Criteria:

- Age between 50 - 70 years of both gender,

- sacroiliac pain with at least 3 of the 5 provocative tests are positive,

- pain did not relieved by the conservative therapy (rest, ice/heat, topical menthol,
lidocaine patch, pelvic belt, physical therapy and NSIAD) for 4 weeks,

- positive diagnostic test 2 ml lidocaine 2% intra-articular SIJ injection one day
before the procedure are included in this study.

Exclusion Criteria:

- The exclusion criteria are patient refusal,

- history of immunosuppression diseases,

- bleeding or coagulation disorders,

- sacroiliac pain of multiple sources,

- local skin infection,

- septic joint, osteomyelitis,

- renal patients (Serum Creatinine >1.8 ),

- decompensated liver diseases,

- local malignancy,

- psychiatric disorders affecting co-operation,

- previous history of chronic opioid use,

- intra articular sacroiliac injection within previous three months,

- negative diagnostic test,

- allergy or hypersensitivity to any of the study medications

- diabetes mellitus, type II with history of poor glycemic control

- morbid obesity ( BMI> 40 ).